Clinical Trial

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Study acronym: (STOP-PAH)
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-06; most recent amendment 2026-04-21.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT06872112
Lead Sponsor Joseph C. Wu
Conditions Pulmonary Arterial Hypertension (PAH)
Enrollment 15 participants
Start Date 2026-04-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23